>
Switch to:

Biomarin Pharmaceutical Intangible Assets

: $585 Mil (As of Sep. 2021)
View and export this data going back to 1999. Start your Free Trial

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Biomarin Pharmaceutical's intangible assets for the quarter that ended in Sep. 2021 was $585 Mil.


Biomarin Pharmaceutical Intangible Assets Historical Data

The historical data trend for Biomarin Pharmaceutical's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Intangible Assets
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 750.82 714.55 688.85 653.62 613.47

Biomarin Pharmaceutical Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Intangible Assets Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 623.37 613.47 1,008.01 590.50 584.69

Biomarin Pharmaceutical Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.


Biomarin Pharmaceutical  (NAS:BMRN) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


Biomarin Pharmaceutical Intangible Assets Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Intangible Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical Business Description

Biomarin Pharmaceutical logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin's Roctavian (hemophilia A gene therapy) and vosoritide (treatment for achondroplasia) are poised to potentially launch in the 2021-22 timeframe.
Executives
Ajer Jeffrey Robert officer: EVP, Chief Commercial Officer C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949
Heron Elaine J director 6 STONEGATE RD PONTOLA VALLEY CA 94028
Pyott David E I director C/O ALLERGAN 2525 DUPONT DRIVE IRVINE CA 92612
Grey Michael G director C/O SGX PHARMACEUTICALS, INC. 10505 ROSELLE STREET SAN DIEGO CA 92121
Fuchs Henry J officer: President, Worldwide R&D C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949
Acosta Andrea officer: GVP, Chief Accouning Officer C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST SAN RAFAEL CA 94901
Dere Willard H director ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320-1799
Lawlis V Bryan director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: LAWLIS V BRYAN a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Anderson Elizabeth M director 10 FINDERNE AVENUE BUILDING 10 BRIDGEWATER NJ 08807
Hombach Robert J. director C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Slamon Dennis director 770 LINDARO STREET SAN RAFAEL CA 94901
Meier Richard A director 1700 E ST ANDREW PLACE SANTA ANA CA 92705
Bienaime Jean Jacques director, officer: Chief Executive Officer 925 PAGE MILL ROAD PALO ALTO CA 94304
Guyer Charles Greg officer: EVP, Chief Technical Officer C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL CA 94901
Mueller Brian officer: EVP, Chief Financial Officer C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949

Biomarin Pharmaceutical Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)